Clinical Trial Update: Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating an increased dose of icotinib in patients with non-small cell lung cancer who previously received gefitinib is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 4 | Status: SUSPENDED